Edwards Lifesciences beats quarterly estimates on robust demand for artificial heart valves

Edwards Lifesciences beat Wall Street first-quarter estimates on Thursday, driven by robust demand ​for its artificial valves used in complex ‌cardiac procedures, sending its shares up over 4% in extended trading.